|
시장보고서
상품코드
2051083
GLP-1 수용체 작용제 시장 : 약물 종류별, 투여 경로별, 용도별, 유통 채널별, 지역별GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
GLP-1 수용체 작용제 시장은 2026년에 317억 1,000만 달러로 추정되며, 2033년에 723억 3,000만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 12.5%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 317억 1,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 12.50% | 2033년 시장 규모 예측: | 723억 3,000만 달러 |
GLP-1 수용체 작용제는 제2형 당뇨병 치료에 있어 중요한 항당뇨병제 계열입니다. 이들은 식사 후 분비되는 펩타이드 호르몬인 내인성 글루카곤 유사 펩타이드 1(GLP-1)의 작용을 모방하여 혈당 의존적으로 인슐린 분비를 자극하고 글루카곤 분비를 억제하는 역할을 합니다. GLP-1 수용체에 결합하여 활성화시킴으로써 인슐린 분비를 유도하고, 글루카곤의 방출을 억제하고, 식욕을 억제하고, 당뇨병 환자의 체중 감소를 촉진합니다. 다른 약제에 비해 우수한 혈당 조절 효과와 낮은 저혈당 위험성이 매력적인 대안으로 작용하여 시장 성장을 견인하고 있습니다.
시장 역학
세계 GLP-1 수용체 작용제 시장의 성장은 전 세계 당뇨병 유병률 증가와 GLP-1 수용체 작용제의 우수한 치료 효과에 의해 주도되고 있습니다. 비만율의 증가는 제2형 당뇨병의 위험을 증가시킬 수 있으며, 이에 따라 보다 효과적인 치료법에 대한 수요가 증가하고 있습니다. 그러나 높은 개발 비용과 엄격한 규제 당국의 승인 절차가 시장 성장을 저해할 수 있습니다. 개선된 제형, 유연한 투여 옵션, 연장된 작용 시간, 다양한 적응증에 사용할 수 있는 신제품 출시는 성장 기회를 가져올 수 있습니다. 각 제조사들은 임상 적응증 확대와 환자 편의성 향상을 위한 경구제 개발을 위해 연구개발(R&D)에 투자하고 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 GLP-1 수용체 작용제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 등급 향상, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 GLP-1 수용체 작용제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 GLP-1 수용체 작용제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 GLP-1 수용체 작용제 시장 : 약물 종류별, 2021-2033년
제5장 GLP-1 수용체 작용제 시장 : 투여 경로별, 2021-2033년
제6장 GLP-1 수용체 작용제 시장 : 용도별, 2021-2033년
제7장 GLP-1 수용체 작용제 시장 : 유통 채널별, 2021-2033년
제8장 GLP-1 수용체 작용제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌과 조사 방법
KSMGLP-1 Receptor Agonist Market is estimated to be valued at USD 31.71 Bn in 2026 and is expected to reach USD 72.33 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 31.71 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.50% | 2033 Value Projection: | USD 72.33 Bn |
GLP 1 receptor agonists are an important class of anti diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon like peptide 1 (GLP 1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose dependent manner. By binding to and activating the GLP 1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.
Market Dynamics
Global GLP 1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP 1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global GLP 1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
- Global GLP 1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global GLP 1 receptor agonist market.
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Parenteral
- Oral
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Eli Lilly and Company
- Sanofi
- Novo Nordisk A/S
- AstraZeneca
- Perrigo Company PLC
- 3M Company
- Bausch Health
- Taro Pharmaceutical Industries
- Novan Inc.
- Serum Institute of India Pvt. Ltd.
- Orgenesis biotech company
- Verrica Pharmaceuticals
- AbbVie Inc.
- Lee's Pharmaceutical Holdings Ltd.
- Cassiopea
- Glenmark Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. GLP-1 Receptor Agonist Market, By Drug Class, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Exenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Liraglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dulaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lixisenatide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Albiglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Semaglutide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. GLP-1 Receptor Agonist Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. GLP-1 Receptor Agonist Market, By Application, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Type 2 Diabetes Mellitus
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Obesity
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Liver Cirrhosis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Non-alcoholic Steatohepatitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. GLP-1 Receptor Agonist Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. GLP-1 Receptor Agonist Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Eli Lilly and Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Perrigo Company PLC
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- 3M Company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bausch Health
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taro Pharmaceutical Industries
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novan Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Serum Institute of India Pvt. Ltd.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Orgenesis biotech company
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Verrica Pharmaceuticals
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Lee's Pharmaceutical Holdings Ltd
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Cassiopea
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Method Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
